Researchers aimed to synthesize the currently available literature on anti-NGF antibodies in OA pain and further determine whether these antibodies are associated with more change in scores for pain and physical function, patient global assessment scores, and AE incidence.
Tanezumab is a humanized monoclonal antibody that selectively targets, binds to, and inhibits nerve growth factor.
The final results of a prospective investigational device exemption trial of GAE for the treatment of moderate-to-severe knee osteoarthritis presented.
Digitally delivered exercise programs benefit pain and functional outcomes among patients with knee osteoarthritis compared with routine self-management.
Weight loss is associated with reduced pain, improved function, and better quality of life in patients with knee OA who are overweight or obese.
The total lifetime opioid-related costs generated by symptomatic knee osteoarthritis (SKOA) in the United States are $14.0 billion.
An evidence-based guideline for the comprehensive management of osteoarthritis , including educational, behavioral, psychosocial, and physical interventions, as well as pharmacologic therapies from the American College of Rheumatology (ACR) and the Arthritis Foundation.
This study explored, the natural course of hip osteoarthritis in patients with first-time hip complaints by tracking their symptoms, physical functioning, and radiographic osteoarthritis features over time.
Findings compared with low-intensity strength training or control condition
Most patients with osteoarthritis of the knee who undergo medial opening wedge HTO do not undergo total knee replacement within 10 years.
